Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial
2026年8月17日 更新者:Shanghai Eye Disease Prevention and Treatment Center
Pre-myopia refers to a condition in which children have not yet developed myopia but exhibit insufficient hyperopic reserve (≤ +0.75 D).
This is particularly relevant for young children aged 6 years and under; if their hyperopic reserve is depleted prematurely and they progress into the pre-myopia stage, the likelihood of developing myopia or even high myopia in the future becomes extremely high.
Therefore, this study plans to conduct a parallel-design, open-label, single-center randomized controlled clinical trial to evaluate the efficacy and safety of artificial intelligence-assisted defocus incorporated multiple segments (DIMS) based spectacle lens in preventing and controlling myopia in pre-myopic children aged 3 to 6 years.
研究概览
地位
尚未招聘
研究类型
介入性
注册 (估计的)
128
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Xiangui He, Prof
- 电话号码:+86 15000755422
- 邮箱:xianhezi@163.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- Shanghai Eye Disease Prevention and Treatment Center
-
接触:
- Tianyu Cheng, Dr
- 电话号码:+86 18817552005
- 邮箱:s70444@126.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
不
描述
Inclusion Criteria:
- Age between 3 and 6 years (inclusive), regardless of gender or ethnicity.
- Cycloplegic spherical equivalent refraction (SER) of the worse eye > -0.50 D and ≤ +0.75 D, absolute cylindrical power ≤ 1.0 D, anisometropia ≤ 1.5 D.
- Best corrected monocular distance high contrast VA ≥ 0.5 for ages 3-5; ≥ 0.7 for age 6.
- At least one parent with SER ≤-3.00D
Exclusion Criteria:
- Individuals with any ocular or systemic diseases that may affect vision and refractive development (e.g., keratoconus, abnormalities in lens shape or position, Marfan syndrome, retinopathy of prematurity, etc.).
- Individuals with known allergies or contraindications to cycloplegic agents.
- Previous use of myopia management treatment (spectacles, atropine; CLs).
- Individuals with binocular vision abnormalities: manifest strabismus, monocular suppression, abnormal fusion function, or impaired stereopsis.
- Individuals unable to cooperate with examinations or communicate.
- Any other conditions deemed by the investigator as unsuitable for participation in the study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Control group
Wear smartwatches
|
Inserted prompt system of the smartwatches can remind the users to go outside.
Inserted sensors can record outdoor parameters such as outdoor time, light intensity, activity pattern, etc.
|
|
实验性的:Intervention group
Wear AI-assisted DIMS-based spectacle lens (at least 10 hours a day), as well as smartwatches
|
Inserted prompt system of the smartwatches can remind the users to go outside.
Inserted sensors can record outdoor parameters such as outdoor time, light intensity, activity pattern, etc.
The AI-DIMS defocus spectacle frame, featuring DIMS-based lenses and an intelligent AI frame, is designed to be worn for at least 10 hours per day.
The frame automatically tracks and records wearing duration parameters.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Changes in axial length
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Changes in Cycloplegic Spherical Equivalent Refraction (SER)
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
|
Changes in Choroidal Thickness (CT)
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
|
Spectacle-wearing compliance and spectacle-wearing time
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Changes in Pupil Diameter
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
|
Changes in Intraocular Pressure (IOP)
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
|
Changes in Best Corrected Visual Acuity
大体时间:From baseline to the 12-month follow-up
|
From baseline to the 12-month follow-up
|
|
Adverse event profile
大体时间:At 12-month follow-up
|
At 12-month follow-up
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:He, Prof、Shanghai Eye Disease Prevention and Treatment Center
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年9月12日
初级完成 (估计的)
2028年5月31日
研究完成 (估计的)
2028年8月31日
研究注册日期
首次提交
2026年8月11日
首先提交符合 QC 标准的
2026年8月11日
首次发布 (实际的)
2026年8月14日
研究记录更新
最后更新发布 (实际的)
2026年8月18日
上次提交的符合 QC 标准的更新
2026年8月17日
最后验证
2026年8月1日
更多信息
与本研究相关的术语
其他研究编号
- IIT2026-003-AMD-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.